title: Ethanol inhibition of insulin signaling in hepatocellular carcinoma cells.
abstract: Chronic ethanol toxicity impairs liver regeneration, inhibits DNA synthesis, and mutes cellular responses to growth factor stimulation. Previous studies demonstrated that the adverse effects of ethanol are mediated by inhibition of tyrosyl phosphorylation of the insulin receptor and the insulin receptor substrate-type 1 (IRS-1). However, overexpression of IRS-1 leads to increased DNA synthesis and cellular transformation due to constitutive activation of mitogen-activated protein (MAP) kinase. The present study examines the effects of ethanol on insulin signaling through IRS-1 in FOCUS hepatocellular carcinoma cells, which overexpress IRS-1, to determine whether such cells were resistant to the inhibitory effects of ethanol. The results demonstrated that ethanol treatment (100 mM) caused 30 to 50% reductions in the levels of insulin-stimulated tyrosyl phosphorylation of the insulin receptor beta-subunit, tyrosyl phosphorylation of IRS-1, phosphorylation of Erk2, association of phosphatidylinositol-3 kinase with tyrosyl-phosphorylated IRS-1, and MAP kinase and phosphatidylinositol-3 kinase activities. In contrast, ethanol treatment had no effect on epidermal growth factor-stimulated tyrosyl phosphorylation of Shc. Corresponding with the pronounced inhibition of MAP kinase, ethanol treatment resulted in 30 to 50% reductions in the expression levels of two important insulin-responsive genes: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and proliferating cell nuclear antigen (PCNA). The findings suggest that, in FOCUS hepatocellular carcinoma cells, which overexpress IRS-1, ethanol treatment substantially inhibits IRS-1 and MAP kinase signaling and growth-associated gene expression, but has no effect on Shc phosphorylation, which activates p21ras through an IRS-1 independent pathway.
authors.affiliation: MGH East Cancer Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
authors.forename: K
authors.initials: K
authors.lastname: Banerjee
authors.forename: L
authors.initials: L
authors.lastname: Mohr
authors.forename: J R
authors.initials: JR
authors.lastname: Wands
authors.forename: S M
authors.initials: SM
authors.lastname: de la Monte
mesh_terms: D006528:Carcinoma, Hepatocellular; D004305:Dose-Response Relationship, Drug; D000431:Ethanol / Q000633:toxicity*; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000235:genetics; D006801:Humans; D007328:Insulin / Q000502:physiology*; D055504:Insulin Receptor Substrate Proteins; D008113:Liver Neoplasms; D008115:Liver Regeneration / Q000187:drug effects*; D010750:Phosphoproteins / Q000235:genetics; D018809:Proliferating Cell Nuclear Antigen / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects*; D014407:Tumor Cells, Cultured / Q000187:drug effects*
chemical_list: C526292:IRS1 protein, human; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; D010750:Phosphoproteins; D018809:Proliferating Cell Nuclear Antigen; D000431:Ethanol; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases